On January 24, 2024 VerImmune, Inc., a biotechnology company specializing in Virus-inspired Particle modalities for cancer treatment and other disease areas, proudly reported the issuance of its third U.S. Patent from the U.S. Patent and Trademark Office (USPTO) (Press release, VerImmune, JAN 24, 2024, View Source [SID1234639454]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The newly issued patent, U.S. Patent No. 11,858,964 B2, appropriately titled "Virus-inspired Compositions and Methods of Redirecting Pre-existing Immune Responses for the Treatment of Cancer," provides a comprehensive layer of protection and support for VerImmune’s ViP proprietary technology platform. This patent includes a novel ViP composition of matter, along with innovative methods for manufacturing and utilizing the technology in cancer treatment. This patent will safeguard the technology platform until at least 2041, which offers an extensive period of exclusivity and protection.
Additionally, VerImmune is also pleased to also announce that the USPTO has issued a notice of allowance for a continuation patent building upon the success of its previously issued patent, U.S. Patent No. 11,285,203, entitled "Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses," This new additional patent will provide additional claim scope, broadening the protection of VerImmune’s first issued patent family.
Collectively, these latest developments further solidify VerImmune’s intellectual property moat at the forefront of cutting-edge cancer treatment technologies.
VerImmune’s revolutionary platform is currently focused on redirecting the body’s pre-existing T-cell memory against pathogens, effectively harnessing its power to combat cancer. With the potential to target multiple types of cancer, the technology’s versatility arises from the near-universal nature of pre-existing responses triggered by childhood vaccines and past infections. As a result, VerImmune’s patented technology holds promise for broad applications in cancer treatment, marking a significant stride towards more effective and inclusive solutions.